查看更多考评等级 近日，一份涉及湖北襄阳某民营医院的文件截图在部分投资者社群及社交平台流传。该文件内容显示， 当地有关部门在对襄阳恒泰康医院进行检查时，发现其存在多项管理问题。由于文件中出现"爱尔"字 样，市场迅速将其与上市公司爱尔眼科医院集团股份有限公司联系起来，引发投资者对其旗下医院管理 合规性的担忧。 面对突如其来的舆论风波，爱尔眼科反应迅速。公司通过其官方投资者关系平台及权威财经媒体发布 《郑重声明》，明确表示："经公司全面核查，襄阳恒泰康医院并非爱尔眼科旗下医院，爱尔眼科从未 投资、入股或参与该医院的任何经营管理活动。" 声明强调，公司所有下属医院均在官网清晰列示，呼 吁公众和投资者以官方信息为准，并表示对任何不实信息和恶意关联的传播保留追究法律责任的权利。 结尾： 截至发稿，传闻源头文件的具体情况尚未得到官方证实。爱尔眼科的快速澄清暂时平息了资本 市场的疑虑，但事件也再次为所有通过并购成长的医疗连锁企业敲响了警钟：在追求规模的同时，品牌 保护的防火墙必须同步筑牢。 注：本文由AI 生成，请仔细甄别 责任编辑：AI观察员 尽管澄清及时，但市场情绪仍受到短暂冲击。声明发布前，爱尔眼科股价盘中出现小幅波 ...

Core Viewpoint - The chairman of Aier Eye Hospital, Chen Bang, is implicated as the actual controller of a mental hospital involved in insurance fraud, raising concerns about the company's governance and reputation [1][4][20]. Group 1: Company Background - Aier Eye Hospital, founded by Chen Bang, is a leading eye care provider in China, having gone public in 2009 as the "first eye care stock" in the country [25]. - Chen Bang has a diverse background, initially facing challenges in various business ventures before successfully establishing Aier Eye Hospital [24][25]. Group 2: Allegations and Investigations - Recent reports allege that several mental hospitals, including Xiangyang Hengtai Kang Hospital, have been involved in fraudulent activities, luring normal individuals to claim insurance benefits [1][4]. - The hospital in question was established in 2019 and is controlled by Chen Bang through a complex ownership structure, holding 59.0333% of the shares [17][19]. Group 3: Market Reaction - Following the allegations, Aier Eye Hospital's stock price fell nearly 4%, closing at 11.07 yuan per share, with a market capitalization of 103.232 billion yuan [20]. - Investors express skepticism regarding the company's governance, questioning Chen Bang's ability to manage the situation effectively [22]. Group 4: Industry Context - The mental health sector in China has seen rapid expansion, with the number of mental hospitals increasing from a few hundred to over 2,500 between 2010 and 2020, often leading to fraudulent practices [29]. - Reports indicate that some hospitals have been fabricating treatment plans to exploit insurance funds, with significant financial gains reported from such activities [29].

Market Overview - A-shares experienced fluctuations with major indices initially rising before closing lower; the Shanghai Composite Index fell by 0.25% to 4065.58 points, while the Shenzhen Component Index and the ChiNext Index dropped by 0.33% and 0.73% respectively [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 2.16 trillion yuan, a decrease of about 300 billion yuan from the previous day [1] Sector Performance - The tourism, liquor, and retail sectors collectively declined, while the oil, chemical, and power sectors showed strength [1] - The oil sector saw significant gains, with stocks like Zhuan Oil and Intercontinental Oil rising to their daily limits; Zhuan Oil opened at the limit down but rebounded to close at the limit up, showcasing a "floor to ceiling" trading pattern [3][4] - The chemical sector also performed well, with Jiangtian Chemical rising nearly 12% and several other stocks hitting their daily limits due to price increases in various chemical products [7] - The lithium battery sector surged, with stocks like Zhenyu Technology and Wanrun New Energy rising over 10% [9][10] - The robotics sector was active, with stocks such as Kailong High-Tech and Tianqi Co. reaching their daily limits [13][14] Oil Market Insights - WTI and Brent crude oil futures both rose by over 1% [6] - Analysts predict that the Brent oil price will stabilize between $55 and $65 per barrel by 2026, while WTI is expected to range from $52 to $62 per barrel [6] Chemical Sector Dynamics - The chemical sector is experiencing price increases across multiple products, driven by the cancellation of export tax rebates, which has accelerated export activities [7] - The "anti-involution" policy is expected to strengthen supply-side constraints, benefiting certain sub-industries such as chlor-alkali, pesticides, and polyester filament [7] Lithium Battery Sector Outlook - The lithium battery sector is projected to improve in supply and demand dynamics by 2025, with product prices and corporate profitability expected to stabilize [11] - The average market price of battery-grade lithium carbonate has exceeded 140,000 yuan per ton, reflecting a 140% increase from the 2025 low [10] Robotics Sector Developments - The humanoid robot sector is gaining traction, with significant developments expected in 2026, including the mass production of Tesla's Optimus robot [15] - The upcoming Spring Festival Gala will feature a diverse lineup of robotics companies, indicating a growing interest and investment in this technology [15]

紧急澄清。 爱尔眼科（300015）2月6日发布公告称，公司关注到部分媒体关于精神专科医院涉嫌违规问题的报道中，将襄阳恒泰康医院有限 公司（以下简称"襄阳恒泰康"）与爱尔眼科直接关联。公司现就有关情况澄清说明如下： 襄阳恒泰康非爱尔眼科所属企业。 该公 司为爱尔医疗投资集团有限公司（简称"爱尔医疗投资"）与其他投资方合资设立的四级子公司。襄阳恒泰康由其医院管理团队经 营。爱尔医疗投资不参与襄阳恒泰康的日常经营管理。爱尔眼科与湖南恒泰康康复医疗产业发展有限公司及其下属机构不存在股 权控制、业务关联或经营管理关系。 公告还称，公司及实际控制人陈邦始终坚持依法合规经营，严格执行国家关于医疗服务、医保基金使用和患者权益保护的相关法 律法规，对任何违法违规行为持"零容忍"态度。 二级市场上，截至2月6日收盘，爱尔眼科跌3.82%，股价报11.07元/股，总市值为1032亿元。 综合自：公司公告等 责编：李丹 校对：杨立林 版权声明 证券时报各平台所有原创内容，未经书面授权，任何单位及个人不得转载。我社保留追 究相关 行 为主体法律责任的权利。 据媒体此前报道，湖北多家精神专科医院被曝可能存在虚构诊疗项目、套取医保资金等 ...

记者丨 李依农 技术将对经济产生变革性影响 编辑丨李莹亮 和佳 2026年伊始，全球经济正回归长期潜在增长轨道，信贷逐步修复，市场信心边际回升。瑞银全 球经济和策略研究主管卡普顿（Arend Kapteyn）在接受南方财经记者专访时表示，在利差收 窄、汇率波动有限且市场流动性充足的背景下，股票仍是最具优势的资产类别，美股今年预计 可涨约10%，欧洲与日本市场也有望录得约8%的涨幅。 他对中国经济保持乐观：新兴经济部门已贡献约四分之一的增长，是推动整体经济的重要动 力。他建议投资者在新兴市场中重点关注中国与巴西，这不仅可获取AI相关敞口，也兼顾估值 与盈利增长优势。 同时，他提醒，投资者仍需关注美国潜在的财政刺激、劳动力市场结构性风险以及整体不确定 性，这些因素可能成为全球市场的主要风险；相比之下，地缘政治因素虽然难以预测，但对金 融市场的直接冲击或相对有限。 卡普顿。资料图 中国在全球新经济领域领先 南方财经： 我们把目光转向中国。怎么看中国经济前景？未来推动经济增长的主要动 力会来自哪些方面？ 卡普顿： 现在还处在年初阶段，我们的预测通常还会经历多次调整。 我们认为，新兴经济部门对整体经济增长的贡献，已经接 ...

Group 1 - Aier Eye Hospital clarified that it has no direct equity or operational management relationship with Xiangyang Hengtai Kang Hospital, which is a joint venture established by Aier Medical Investment Group and other investors [1] - Aier Medical Investment does not participate in the daily operations of Xiangyang Hengtai Kang Hospital, and there is no equity control or business relationship with Hunan Hengtai Kang Rehabilitation Medical Industry Development Co., Ltd [1] Group 2 - Eli Lilly reported a total revenue of $65.179 billion for 2025, a 45% year-on-year increase, with its star product, Tirzepatide, generating $36.507 billion in sales [2] - The company provided guidance for 2026, expecting revenue to reach between $80 billion and $83 billion, with non-GAAP EPS projected between $33.50 and $35.00 [2] Group 3 - Novo Nordisk's revenue for 2025 is projected to grow by 6% to 309.1 billion Danish Krone, with a 10% increase at fixed exchange rates [3] - Sales in the Greater China region for rare diseases grew by 84% year-on-year at fixed exchange rates, driven by sales in rare blood diseases [3] - The company plans to propose a dividend of 7.95 Danish Krone per share for 2025, totaling 11.70 Danish Krone for the year, and has initiated a stock buyback program of up to 15 billion Danish Krone [3] Group 4 - Innovent Biologics achieved total product revenue of approximately 11.9 billion Yuan in 2025, a year-on-year increase of about 45% [4] - The company expanded its oncology product portfolio to 13 products, with core products like Tyvyt (sintilimab injection) showing steady growth [4] - The company successfully entered the chronic disease commercialization field, with key products contributing significantly to revenue growth [5] Group 5 - Sequoia China completed the global acquisition of moxifloxacin business, establishing Hangzhou Sequoia Biopharmaceutical Co., Ltd, with former Pfizer executive Jin Xiaodong appointed as CEO [6] - The acquisition includes specific assets related to moxifloxacin, ensuring a solid foundation for the product's continued supply and future development [6] Group 6 - Jiashitang announced a change in its controlling shareholder to Tongrentang Group, following a share transfer agreement with Everbright Industrial and Everbright Health [7] - The transfer involves significant shareholdings, leading to a change in the actual controller to the State-owned Assets Supervision and Administration Commission of Beijing [7]

专题：爱尔眼科董事长陈邦，疑似为"骗保"精神病院实控人 来源：基本面解码 2026年2月6日，对于中国著名的"白马股"爱尔眼科及其掌舵人陈邦而言，无疑是一个遭遇信任危机的至 暗时刻。当日午盘，爱尔眼科股价应声下跌3.48%，最新市值定格在1036亿元附近。引发这场资本市场 震荡的导火索，并非来自爱尔眼科上市体系内的直接经营风险，或是一场源自"体外"的道德与法律风险 ——湖北多家精神病医院被权威媒体曝光涉嫌虚构诊疗项目、套取医保资金。在这一连串触目惊心的违 规名单中，襄阳恒泰康医院赫然在列，而经过股权穿透，其背后的实际控制人或指向爱尔眼科的灵魂人 物：陈邦。 尽管上市公司火速发布澄清公告，试图在"爱尔眼科"与"涉事医院"之间建立一道严密的物理与法律防火 墙，强调涉事主体仅为控股股东旗下的四级子公司，非上市公司所属。然而，在资本市场与公众舆论的 审视下，这道防火墙似乎难以完全隔绝"信任危机"的蔓延。 紧急切割：资本高手的"防火墙"战术 面对突如其来的舆情，爱尔眼科的反应堪称教科书级别的危机公关。2月6日午间，公司迅速发布公告， 核心逻辑清晰明确：切割。 公告指出，襄阳恒泰康医院有限公司并非爱尔眼科所属企业，而是控 ...

以下文章来源于21新健康 ，作者韩利明，朱艺艺 事件进一步牵出资本市场关联。2月5日晚间有媒体指出，涉案的襄阳恒泰康医院实际控制人为爱尔眼科（300015.SZ）实控人陈邦。 对于双方的关系，2月6日，21世纪经济报道记者联系爱尔眼科相关人士获得一份回应称， "襄阳恒泰康医院有限公司并非爱尔眼科体系 内企业。该公司为爱尔医疗投资集团有限公司与其他社会资本方合资设立的四级子公司，与爱尔眼科无任何股权关联和业务关系。作为 投资人之一，陈邦并不直接参与恒泰康的经营管理。" 但二级市场已率先作出反应。截至2月6日14:20，爱尔眼科收报11.12元/股，下跌3.39%，总市值1037亿元。 | | 11.12 -0.39 -3.39% | | | | | 麦尔根科 立即 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 300015 父易 | | | SZSE CNY 14:19:24 交易中 查看L2全景 | | | | | 通融公 ○ + | | 委比 | 58.65% 委差 | 28228 | | Wind ESG评级 AA | | 详情 | ...

| | 3 | 豆包 - 字节跳动旗下 Al 助手 | FE HT | | --- | --- | --- | --- | | | | Al 全智能聊天对话问答助手,搜 ... | | | | 4 | 抖音精选-看视频 精选作者贺新春 | MEELS | | | | | App 内购买 | | | 5 | 蚂蚁阿福-蚂蚁旗下 Al健康 助手 健康是福,健康的事就找阿福 | EE HT | | | 6 | 汽水音乐 - 随时听好歌 随时随地,懂你想听 | FE Har | | | 7 | 红果短剧 - 海量热门短剧 随心看 海量高清短剧视频内容,追剧必 ... | | | | 8 | 抖音商城 抖音电商官方平台 | SES EN | | | | | App 内购买 | | Today | | 游戏 App | | 据九派新闻，因为千问免单活动订单比较多，从上午就开始爆单。目前囤了100多单，现在线 下下单还需要等1个多小时。 记者丨张 嘉钰 孔海丽 编辑丨江佩霞 据财联社，多名用户反馈，继屏蔽千问分享口令后， 腾讯自家AI产品元宝的春节活动分享口 令，在微信平台中同样已不可复制。 今日千问开启免单奶茶活动后，已 ...

Market Overview - The A-share market experienced a slight decline, with the Shanghai Composite Index down 0.25% to 4065 points, briefly dipping to 4029 points during the day [1] - The Shenzhen Component Index fell by 0.33%, and the ChiNext Index decreased by 0.73% [1][2] - Total market turnover was 2.16 trillion yuan, a decrease of 308 billion yuan from the previous trading day, with over 2700 stocks rising [1] Sector Performance - The mining and oil sectors saw gains, with stocks like Tongyuan Petroleum and Zhun Oil Co. hitting the daily limit [4] - The fluorochemical sector also performed well, with Tianji Co. reaching the daily limit [4] - Lithium mining and battery sectors were active, with Enjie Co. hitting the daily limit [4] - Conversely, the liquor sector faced declines, with Huangtai Liquor hitting the daily limit down, and Moutai falling by 2.57% [4][5][6] - The commercial retail and duty-free sectors dropped, with Baida Group hitting the daily limit down [4] Notable Stock Movements - Alibaba-related stocks surged, with Dataport hitting the daily limit and several other stocks rising significantly [4] - In the Hong Kong market, major tech stocks like Alibaba and Meituan saw declines, while the lithium battery and new energy vehicle sectors performed well, with NIO rising by 8% [6][8] Commodity Prices - International precious metal prices rebounded, with spot gold rising nearly 1% and recovering above 4900 USD/ounce, while spot silver increased by over 2% [8][9] - Analysts suggest that the current upward trend in gold prices is driven by liquidity expectations and ongoing geopolitical tensions [9] Economic Outlook - The macroeconomic outlook indicates potential for a rebound in both Chinese and global economies within the next 6-12 months, which may support metal prices after adjustments [9][10] - The market is expected to see further upward movement in the stock market, with liquidity being a significant driver of market changes [10]